Coherus BioSciences Files 8-K on Financials
Ticker: CHRS · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1512762
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: CHRS
TL;DR
CHRS filed an 8-K on Jan 13, 2025, covering financials and operations. Details to follow.
AI Summary
On January 13, 2025, Coherus BioSciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. Specific financial figures or operational details were not detailed in the provided excerpt.
Why It Matters
This filing provides investors with crucial updates on Coherus BioSciences' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine financial and operational information, not indicating immediate or significant new risks.
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- Dennis M. Lanfear (person) — Contact Person for Mail and Business Address
- 0001558370-25-000167 (filing_id) — Accession Number
- 20250113 (date) — Filing Date
FAQ
What specific financial results are being reported by Coherus BioSciences in this 8-K?
The provided excerpt does not contain specific financial results; it only indicates that the filing pertains to 'Results of Operations and Financial Condition'.
What is the primary purpose of this 8-K filing for Coherus BioSciences?
The primary purpose is to report on the company's results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.
When was this 8-K filing submitted to the SEC?
The filing was submitted on January 13, 2025.
What is the principal business address of Coherus BioSciences as listed in the filing?
The principal business address is 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
Does the filing mention any specific new products or regulatory updates?
The provided excerpt does not mention any specific new products or regulatory updates; it focuses on the general categories of financial condition and operations.
Filing Stats: 729 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2025-01-13 16:25:13
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
Filing Documents
- chrs-20250113x8k.htm (8-K) — 41KB
- chrs-20250113xex99d1.htm (EX-99.1) — 3KB
- chrs-20250113xex99d1g001.jpg (GRAPHIC) — 174KB
- 0001558370-25-000167.txt ( ) — 440KB
- chrs-20250113.xsd (EX-101.SCH) — 4KB
- chrs-20250113_def.xml (EX-101.DEF) — 3KB
- chrs-20250113_lab.xml (EX-101.LAB) — 12KB
- chrs-20250113_pre.xml (EX-101.PRE) — 11KB
- chrs-20250113x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On January 13, 2025, Coherus BioSciences, Inc. (the "Company") will present its preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2024 and preliminary unaudited cash, cash equivalents and investments as of December 31, 2024 in a public webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the preliminary financial information included in this presentation is furnished as Exhibit 99.1 to this report and the webcast will be available on the Company's investor relations website at https://www.investors.coherus.com as previously announced. Cautionary Note Regarding Preliminary Unaudited Financial Results The Company is providing the preliminary financial information for the quarter and fiscal year ended December 31, 2024 based on currently available information. The Company's financial closing procedures for the quarter and fiscal year ended December 31, 2024 are not yet complete. These procedures may result in changes that could significantly affect such preliminary unaudited results. As a result, the Company's final results for the quarter and fiscal year ended December 31, 2024 may vary materially from the preliminary unaudited results furnished in Exhibit 99.1. The Company's independent registered public accounting firm has not reviewed or audited the financial results presented in this announcement.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The Company also noted that due to strong demand in Q4 2024 and into Q1 2025, all three presentations of UDENYCA are being temporarily allocated. The information furnished pursuant to Item 2.02 and Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Slide from Company presentation dated January 13, 2025 104 Cover page Interactive Data file (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer